Tag: Aurobindo Pharma
GENERAL Aurobindo Pharma Signs Licensing Agreement With MSD For HIV Drug

Aurobindo Pharma Ltd  has entered into a non-exclusive voluntary licensing agreement with MSD (the trade name of Merck & Co., Inc., Rahway, New Jersey, USA) to manufacture and supply a generic version of the investigational HIV prevention medicine, Alimatravir, in eligible low- and middle-income countries. Aurobindo Pharma is among a select group of global generic […]

CW Bureau · Jul 25, 2026
GENERAL Aurobindo Pharma To Acquire 80% Stake In A1 Biochem CRO Business

Aurobindo Pharma Ltd, through its wholly owned subsidiary Apitoria Pharma Pvt Ltd, will acquire an 80% stake in the Contract Research Services business of A1 Biochem Group. The acquisition will be completed within 90 to 120 days for cash consideration at an enterprise value of $17 million on a debt-free and cash-free basis. Building CRDMO […]

CW Bureau · Jul 24, 2026
GENERAL Aurobindo Eyes $494-Mn US Market With Launch Of Tofacitinib Generic

Aurobindo Pharma has strengthened its presence in the lucrative US generics market after receiving final approval from the US Food and Drug Administration (USFDA) for Tofacitinib tablets in 5 mg and 10 mg strengths, opening the door to a market worth nearly $500 million annually. The approval allows the company to manufacture and market a […]

CW Bureau · Jun 4, 2026
GENERAL Aurobindo Pharma Gets USFDA Nod For Dapagliflozin-Metformin Combo

Aurobindo Pharma Ltd has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Dapagliflozin and Metformin Hydrochloride extended-release tablets in multiple strengths such as 5 mg/500 mg, 5 mg/1000 mg, 10 mg/500 mg, and 10 mg/1000 mg. The approved formulation is bioequivalent and therapeutically equivalent to the reference listed […]

CW Bureau · Apr 7, 2026
GENERAL CuraTeQ Biologics Reports Positive Phase 3 Results For BP11 Biosimilar

CuraTeQ Biologics Pvt Ltd, a wholly owned subsidiary of Aurobindo Pharma Ltd, has announced positive top-line results from its Phase 3 clinical study of BP11, an investigational biosimilar to Xolair (omalizumab). Study meets primary endpoints in CSU patients According to the company, the study successfully met all primary endpoints, demonstrating high comparability with the reference […]

CW Bureau · Apr 6, 2026
GENERAL Aurobindo Arm Eugia Secures USFDA Nod For Everolimus Tablets

Aurobindo Pharma has strengthened its US generics portfolio after its wholly owned subsidiary, Eugia Pharma Specialities, received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Everolimus tablets in multiple strengths. The approval covers Everolimus tablets in 0.25 mg, 0.5 mg, 0.75 mg and 1 mg strengths. The product is […]

CW Bureau · Feb 26, 2026